<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1483055</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1483055</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>Alhagi maurorum</italic> extract in combination with lytic phage cocktails: a promising therapeutic approach against biofilms of multi-drug resistant <italic>P. mirabilis</italic>
</article-title>
<alt-title alt-title-type="left-running-head">Mirzaei et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1483055">10.3389/fphar.2024.1483055</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mirzaei</surname>
<given-names>Arezoo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1231421/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Esfahani</surname>
<given-names>Bahram Nasr</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1442627/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghanadian</surname>
<given-names>Mustafa</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2567608/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wagemans</surname>
<given-names>Jeroen</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/703720/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lavigne</surname>
<given-names>Rob</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/267378/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Moghim</surname>
<given-names>Sharareh</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1231418/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Bacteriology and Virology</institution>, <institution>School of Medicine</institution>, <institution>Isfahan University of Medical Sciences</institution>, <addr-line>Isfahan</addr-line>, <country>Iran</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Pharmacognosy</institution>, <institution>School of Pharmacy</institution>, <institution>Isfahan University of Medical Sciences</institution>, <addr-line>Isfahan</addr-line>, <country>Iran</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Biosystems</institution>, <institution>KU Leuven</institution>, <addr-line>Leuven</addr-line>, <country>Belgium</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1786774/overview">Hamid R. Pourianfar</ext-link>, Industrial Fungi Biotechnology Research Department Research Institute for Industrial Biotechnology Academic Center for Education, Iran</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/677271/overview">Aim&#xe9; Gabriel Fankam</ext-link>, University of Dschang, Cameroon</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/446988/overview">Shanmugaraj Gowrishankar</ext-link>, Alagappa University, India</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Sharareh Moghim, <email>moghim@med.mui.ac.ir</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1483055</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>08</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>11</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Mirzaei, Esfahani, Ghanadian, Wagemans, Lavigne and Moghim.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Mirzaei, Esfahani, Ghanadian, Wagemans, Lavigne and Moghim</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Antimicrobial resistance (AMR) poses a significant global threat to public health systems, rendering antibiotics ineffective in treating infectious diseases. Combined use of bio compounds, including bacteriophages and plant extracts, is an attractive approach to controlling antibiotic resistance. In this study, the combination of phage cocktail (Isf-Pm1 and Isf-Pm2) and <italic>Alhagi maurorum</italic> crude extract (AME) was investigated in controlling biofilm-forming multi-drug resistant <italic>P. mirabilis</italic> isolates, <italic>in vitro</italic> and a phantom bladder model. The combination of AME and phage cocktails demonstrated no significant disparity in its ability to inhibit quorum sensing (QS) when compared to the individual control of AME alone. Following treatment with the combination of phage cocktail and AME at a 125&#xa0;&#x3bc;g/mL concentration, the MDR <italic>P. mirabilis</italic> biofilm biomass was notably reduced by 73% compared to the control (P&#x3c; 0.0001). The anti-biofilm effect was confirmed by Scanning Electron Microscopy (SEM). Moreover, in a bladder phantom model, there was a considerable decrease in encrustation levels compared to the control. The combined treatment resulted in a 1.85 logarithmic reduction in bacterial adhesion to Vero cells compared to the control. The real-time PCR results indicated significant downregulation of QS- and adhesion-related gens. The phage therapy, combined with AME, holds promising potential in reducing biofilm formation.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="FPHAR_fphar-2024-1483055_wc_abs.tif"/>
</p>
</abstract>
<kwd-group>
<kwd>Alhagi maurorum</kwd>
<kwd>bacteriophage therapy</kwd>
<kwd>
<italic>Proteus mirabilis</italic>
</kwd>
<kwd>biofilm</kwd>
<kwd>combination therapy</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Infectious Diseases</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Highlights</title>
<p>
<list list-type="simple">
<list-item>
<p>&#x2022; Harnessing the Power of Nature: Bacteriophages and Plant Extracts Unite to Overcome Antibiotic Resistance</p>
</list-item>
<list-item>
<p>&#x2022; Blasting Biofilms: Phage Cocktail and AME Reduce MDR <italic>P. mirabilis</italic> Biofilm Biomass by 73%</p>
</list-item>
<list-item>
<p>&#x2022; Clearing the Path: Combination Therapy Significantly Reduces Encrustation Levels in a Bladder Phantom Model</p>
</list-item>
<list-item>
<p>&#x2022; A Shield Against Adhesion: Phage Cocktail and AME Dramatically Reduce Bacterial Attachment to Vero Cells</p>
</list-item>
<list-item>
<p>&#x2022; Silencing the Threat: Real-Time PCR Reveals Downregulation of QS- and Adhesion-Related Genes</p>
</list-item>
</list>
</p>
</sec>
<sec id="s2">
<title>Introduction</title>
<p>Antimicrobial resistance (AMR) is recognized as a significant threat to public health systems worldwide. Infectious diseases can no longer be treated with antibiotics, presenting an uncertain future in healthcare (<xref ref-type="bibr" rid="B6">Chokshi et al., 2019</xref>). In recent years, the focus has shifted towards novel strategies to reduce antibiotic resistance levels, including combined therapies.</p>
<p>
<italic>Proteus mirabilis</italic> is a significant pathogen in urinary tract infections (UTIs), particularly in complicated cases and catheter-associated urinary tract infections (CAUTIs). The incidence of <italic>P. mirabilis</italic> infections notably increases with prolonged catheterization, often affecting vulnerable populations such as patients in nursing facilities and long-term care institutions (<xref ref-type="bibr" rid="B9">Fox-Moon and Shirtliff, 2024</xref>).</p>
<p>These infections pose considerable clinical challenges due to the organism&#x2019;s resistance to commonly used antibiotics. Furthermore, <italic>P. mirabilis</italic> can exacerbate complications such as urolithiasis, potentially leading to irreversible renal impairment. The progression of these infections can also result in serious conditions like bacteremia and sepsis, particularly as the bacteria utilize catheters as pathways for spreading through tissues. This resistance complicates treatment options and underscores the need for effective strategies to combat these infections (<xref ref-type="bibr" rid="B3">Chakkour et al., 2024</xref>).</p>
<p>Bacteriophages and plant extracts are being explored individually or in combination with conventional antibiotics to treat multidrug-resistant (MDR) infections (<xref ref-type="bibr" rid="B4">Cheesman et al., 2017</xref>). Bacteriophages are natural antibacterial agents capable of regulating bacterial populations by inducing bacterial lysis. The lytic activity of phages has been explored against gram-positive (<xref ref-type="bibr" rid="B15">Leprince and Mahillon, 2023</xref>) gram-negative bacteria (<xref ref-type="bibr" rid="B32">Shah et al., 2023</xref>), and MDR pathogens. Specific barriers to applying phages as routine therapy in humans include the emergence and evolution of phage resistance in bacteria and their narrow host range (<xref ref-type="bibr" rid="B40">Zalewska-Pi&#x105;tek, 2023</xref>). Combination of a phage cocktail with antibiotics and/or other antibacterial compounds, such as natural antimicrobial plant extracts, might reduce antibiotic consumption, control antibiotic resistance and phage therapy limitations (<xref ref-type="bibr" rid="B27">Pimchan et al., 2018</xref>). More investigation is needed to explore the possible synergetic effect of the combination of plant extracts and bacteriophages. It has been reported that <italic>Alhagi maurorum</italic> (<italic>A. maurorum</italic>), a traditional medicinal plant in the Middle East, is rich in phenolic and flavonoid compounds (<xref ref-type="bibr" rid="B1">Al-Jaber et al., 2011</xref>). These active ingredients have been shown various therapeutic benefits, including antiviral, antibacterial, anti-inflammatory, and anticarcinogenic activities (<xref ref-type="bibr" rid="B38">Ullah et al., 2020</xref>). The anti-biofilm activity of <italic>A. maurorum</italic> extract on <italic>P. mirabilis</italic> has been investigated previously (<xref ref-type="bibr" rid="B20">Mirzaei et al., 2022a</xref>). The virulent bacteriophages Isf-Pm1 and Isf-Pm2 have been isolated from municipal wastewater and were shown to be able to reduce the concentration of <italic>P. mirabilis</italic> from 10<sup>9</sup>&#xa0;CFU/mL to 10<sup>1.6&#xa0;</sup>CFU/mL in 30&#xa0;min when used as a cocktail at a multiplicity of infection (MOI) of 1 (<xref ref-type="bibr" rid="B22">Mirzaei et al., 2022b</xref>). In this study, we focused on the possible synergetic antimicrobial activity of <italic>A. maurorum</italic> extract (AME) in combination with the phage cocktail in an <italic>in vitro</italic> phantom biofilm model.</p>
</sec>
<sec sec-type="materials|methods" id="s3">
<title>Materials and methods</title>
<sec id="s3-1">
<title>
<italic>Alhagi maurorum</italic> extracts (AME)</title>
<p>The crude extract of <italic>A</italic>. <italic>maurorum</italic> plant was prepared with hydroalcoholic method as described in our previous study (<xref ref-type="bibr" rid="B20">Mirzaei et al., 2022a</xref>). The extraction solvent utilized for the crude extract was water.</p>
</sec>
<sec id="s3-2">
<title>Antibacterial activity of <italic>Alhagi maurorum</italic>
</title>
<p>The minimum inhibitory concentration (MIC) of the AME was determined using the microbroth dilution method, following a previously described protocol (<xref ref-type="bibr" rid="B39">Veiga et al., 2019</xref>). In summary, stock solution of AME (2&#xa0;mg/mL) was subjected to serial two-fold dilution in sterile U-bottom 96-well microplates containing Mueller Hinton Broth (MHB). Subsequently, 100&#xa0;&#x3bc;L of MHB was added to all wells. A 100&#xa0;&#x3bc;L of the extract (2&#xa0;mg/mL) was poured into each well of the first row. Inoculum of 10&#xa0;&#x3bc;L with a concentration of 10<sup>8</sup>&#xa0;CFU/mL was added to each test well. The plates were then covered and incubated at 37&#xb0;C for 24&#xa0;h. Following incubation, the MIC was determined as the lowest concentration of the tested material that visibly inhibited bacterial growth. In the negative control well, no substances were added.</p>
</sec>
<sec id="s3-3">
<title>Bacteriophages and bacterial isolates</title>
<p>Forty <italic>P. mirabilis</italic> isolates were collected from catheters at the intensive care units (ICUs) of reference hospitals in Isfahan, Iran, and identified by conventional biochemical method followed by PCR-sequencing of the <italic>ureG</italic> gene (<xref ref-type="bibr" rid="B21">Mirzaei et al., 2021</xref>). The local ethical committee of Isfahan University of Medical Sciences approved this study (IR.MUI.MED.REC.1401.405). Also, the participants provided written informed consent to participate in this study.</p>
<p>
<italic>P. mirabilis</italic> ATCC7002 was used as a reference strain. The antimicrobial resistance pattern and biofilm formation of isolated bacteria was performed by disk diffusion and microtiter plate according to the Clinical and Laboratory Standards Institute (CLSI<sub>2022</sub>) guidelines and the O&#x27;Toole study (<xref ref-type="bibr" rid="B26">O&#x2019;Toole, 2011</xref>). MDR isolates were classified as those resistant to at least one agent from three or more antimicrobial classes, according to <xref ref-type="bibr" rid="B17">Magiorakos et al. (2012)</xref>. Twelve MDR and strong biofilm-forming clinical isolates were chosen for further investigation (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>).</p>
<p>Pm Isf-1 and Pm Isf-2, lytic phages of <italic>P. mirabilis</italic> ATCC7002, were isolated from Municipal wastewater. The phage isolation and characterization are reported in our previous study (<xref ref-type="bibr" rid="B22">Mirzaei et al., 2022b</xref>).</p>
</sec>
<sec id="s3-4">
<title>Phage-extract interaction assay</title>
<p>In order to test the direct effect of the extract on phage titer and plaque-forming ability, a coincubation assay was performed (<xref ref-type="bibr" rid="B27">Pimchan et al., 2018</xref>). Briefly, 1&#xa0;mL of phage lysates (Pm Isf-1: 10<sup>8</sup>&#xa0;PFU/mL, Pm Isf-2: 10<sup>8</sup>&#xa0;PFU/mL) were sampled and supplemented with 1&#xa0;mL of two-fold serial dilutions of plant extract (62.5&#x2013;1,000&#xa0;&#x3bc;g/mL). Phage lysate alone was used as positive control. The microtubes were incubated at 37&#xb0;C for 24&#xa0;h. The samples were centrifuged at 5,000 &#xd7; g for 5&#xa0;min, and the supernatants (phages) were titered by the double-layer agar method (<xref ref-type="bibr" rid="B7">Clokie et al., 2009</xref>).</p>
</sec>
<sec id="s3-5">
<title>Quantitative anti-quorum sensing (anti-QS) assay</title>
<p>The anti-QS test was performed based on the ability to inhibit the production of the purple pigment violacein by <italic>Janthinobacterium lividum (J. lividum)</italic> ATCC 12472 according to Chenia&#x2019;s method (<xref ref-type="bibr" rid="B5">Chenia, 2013</xref>).</p>
</sec>
<sec id="s3-6">
<title>Anti-biofilm activity of phage-extract combination</title>
<p>To study the anti-biofilm activity of phage-extract on bacteria, a 96-well microplate dilution method was performed. A hundred microliter of the overnight culture of <italic>P. mirabilis</italic> (OD<sub>620nm</sub> of 0.1) suspension were added to a 96-well polystyrene flat-bottomed plate and incubated at 37&#xb0;C for 72&#xa0;h. Then, the media was discarded, and the biofilms were washed with phosphate-buffered saline (PBS) (pH 7.2). Serial dilutions of AME (125&#x2013;1,000&#xa0;&#x3bc;g/mL) were prepared and were added to each biofilm-coated well in combination with the phage cocktail (1:1) at different MOIs (0.1, 1, 10). As a positive control, 100&#xa0;&#x3bc;L of nutrient broth was added to the original biofilm of the <italic>P. mirabilis</italic> isolates. The treated plates were incubated for 18&#xa0;h at 37&#xb0;C. The biofilm biomass was stained by 0.1% crystal violet method and was quantified by measuring the OD<sub>620</sub> using a microtiter plate reader (Infinite F50, Tecan) (<xref ref-type="bibr" rid="B21">Mirzaei et al., 2021</xref>). The experiment was conducted in triplicates.</p>
</sec>
<sec id="s3-7">
<title>Adhesion assay</title>
<p>Vero cells (Pasteur Institute of Iran), seeded in 24-well plates (0.5 &#xd7; 10<sup>5</sup> cells/well), was overlaid with 200&#xa0;&#xb5;L of AME (125&#x2013;1,000&#xa0;&#x3bc;g/mL) and 200&#xa0;&#xb5;L of phage cocktail (MOIs 0.1&#x2013;10). Then, 40&#xa0;&#xb5;L of the <italic>P. mirabilis</italic> suspensions (OD<sub>620nm</sub> &#x3d; 0.1) were added to the wells, followed by incubation at 37&#xb0;C (5% CO<sub>2</sub>) for 3&#x2013;6&#xa0;h. The wells were washed three times with PBS to remove non-adherent bacteria. Cells were then treated with 400&#xa0;&#x3bc;L of 0.025% Triton X-100 for 5&#xa0;min at 37&#xb0;C to detach and lyse the cell monolayer and suspended in 1.6&#xa0;mL phosphate-buffered saline (PBS). Bacterial colonies were counted, and the number of bacterial colonies in the treated plates were compared to the control (<xref ref-type="bibr" rid="B30">Rocha et al., 2007</xref>).</p>
</sec>
<sec id="s3-8">
<title>Biofilm inhibition of combined phage-extract in phantom bladder model</title>
<p>
<italic>In vitro</italic> bladder models, as originally described by <xref ref-type="bibr" rid="B35">Stickler and Morgan (2006)</xref>, were established and maintained at 37&#xb0;C using a double-walled glass chamber. Briefly, after sterilization through of phantom bladder model, size 18 all-silicone Foley catheters were inserted, and retention balloons were inflated with 10&#xa0;mL of sterile water. A sterile urine sample from a healthy male volunteer, free from urinary tract infections, was filtered and pumped into the bladder, creating a residual volume of 30&#xa0;mL. <italic>P. mirabilis</italic> ATCC 7002 cell suspensions (10<sup>8</sup>&#xa0;CFU/mL) were added to this residual urine to simulate late-stage infection and allowed to incubate for 1&#xa0;h. After 45&#xa0;min, the models received a single dose of a two-phage cocktail (2 &#xd7; 10<sup>10</sup>&#xa0;PFU/mL) and AME at the optimal concentration (125&#xa0;&#x3bc;g/mL) in a volume of 1&#xa0;mL, after which flow was restored. Viable cell counts in the residual bladder medium were measured at the beginning and end of the experiments, and pH levels were checked. Additionally, calcium deposition on the catheters was assessed using flame photometry 18&#xa0;h after treatment. In this procedure, 1-cm catheter sections were placed in a solution of 95% ammonium oxalate and 5% oxalic acid, mixed vigorously for 3&#xa0;min, and incubated at room temperature for 30&#xa0;min. After removing the catheter sections, the solution was centrifuged at 3,000 &#xd7; g for 10&#xa0;min, and the supernatant was discarded. The remaining pellets were resuspended in 5&#xa0;mL of 0.05&#xa0;M perchloric acid, mixed well, and centrifuged again at 3,000 &#xd7; g for 2&#xa0;min to collect the supernatants. The calcium concentration in these supernatants was then measured using a flame photometer (<xref ref-type="bibr" rid="B25">Nzakizwanayo et al., 2016</xref>).</p>
</sec>
<sec id="s3-9">
<title>Biofilm inhibition analysis using scanning electron microscopy (SEM)</title>
<p>The biofilm of <italic>P. mirabilis</italic> (10<sup>6</sup>&#xa0;CFU/mL) was formed in a 6-well microtiter plate containing a glass coverslip and incubated at 37&#xb0;C for 72&#xa0;h. The coverslips were subsequently exposed to 1&#xa0;mL of the respective phage cocktail (final 2 &#xd7; 10<sup>10</sup>&#xa0;PFU/mL of each phage) in combination with 1&#xa0;mL of AME (optimal concentration 125&#xa0;&#x3bc;g/mL) and incubated for 18&#xa0;h. Then, the coverslips were rinsed two times with PBS and air-dried in an incubator set to 37&#xb0;C for 20&#xa0;h. The biofilms were fixed with 2.5% glutaraldehyde and dehydrated using a graded ethanol series (30%&#x2013;100%) for 5&#xa0;min. Subsequently, the biofilms were subjected to critical point drying, sputtered with gold, and observed under SEM (FEI, Tecnai G-2S Twin) using an operating voltage of 15&#xa0;kV.</p>
</sec>
<sec id="s3-10">
<title>Evaluation of QS and adhesion gene expression level by real-time PCR</title>
<p>Quantitative real-time PCR (qRT-PCR) assay was performed to determine the effect of the combination of phage - AME on the expression of QS and adhesion genes (<italic>mrp</italic>A, <italic>pmf</italic>A, <italic>lux</italic>S, <italic>rsm</italic>A, and <italic>rsb</italic>A) of <italic>P. mirabilis</italic>. Overnight pooled urine of <italic>P. mirabilis</italic> 7,002 was transferred to fresh urine, treated with an optimal concentration of AME (125&#xa0;&#x3bc;g/mL) and phage cocktail (MOI 1:1), and incubated at 37&#xb0;C for different time intervals (4, 16, and 48&#xa0;h). Total RNA was extracted from bacterial cells using an RNA extraction kit (Jena Bioscience, Germany). The cDNA was synthesized according to the kit protocol (Jena Bioscience, Germany). qRT-PCR was performed on an ABI system (Applied Biosystems StepOne Plus&#x2122;, United States). Each 20&#xa0;&#xb5;L reaction contained 2 &#xd7; Master Mix (SYBR Green Ampliqon, Denmark), diluted cDNA (5&#xa0;ng/L), primers (10 p.m. of each forward and reverse primer), and RNase-free ddH<sub>2</sub>O. The thermocycling conditions were as follows: 10&#xa0;min, 95&#xb0;C, followed by 40 cycles of 15&#xa0;s at 95&#xb0;C, 54&#xa0;&#xb0;C for 60&#xa0;s 16 s rRNA was used as an internal control. The primers used in this study are mentioned in our previous study (<xref ref-type="bibr" rid="B22">Mirzaei et al., 2022b</xref>). All samples were run in triplicate. The conventional 2<sup>&#x2212;&#x394;&#x394;CT</sup> method calculated the relative expression of target genes (<xref ref-type="bibr" rid="B16">Livak and Schmittgen, 2001</xref>).</p>
</sec>
<sec id="s3-11">
<title>Determination of cell viability (MTT assay)</title>
<p>Vero cells (0.5 &#xd7; 10<sup>4</sup> cells/well) were seeded in 96-well microtiter plates in the presence of Dulbecco&#x2019;s Modified Eagle Medium (DMEM, Gibco, United States) supplemented with 5% FBS (Gibco, United States) and incubated for 12&#xa0;h in a humidified atmosphere with 5% CO<sub>2</sub> at 37&#xb0;C. A 100&#xa0;&#x3bc;L of ten-fold serial dilutions of AME (62.5&#x2013;1,000&#xa0;&#x3bc;g/mL) and Phage (MOI<sub>s</sub> 0.01&#x2013;10) were added to each well. Cell viability was assessed 24&#xa0;h post incubation by MTT assay, as previously described (<xref ref-type="bibr" rid="B22">Mirzaei et al., 2022b</xref>).</p>
</sec>
<sec id="s3-12">
<title>Statistical analysis</title>
<p>All statistical analyses were carried out using GraphPad Prism9 (GraphPad Software, San Diego, CA, United States). All results were presented as mean and standard deviation (SD). A two-way ANOVA plus Dunnett&#x2019;s multiple comparisons tests was used to analyze the phage statistically&#x2013;extract coincubation assay results. P-values&#x3c; 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s4">
<title>Results</title>
<sec id="s4-1">
<title>Antibacterial activity of <italic>A. maurorum</italic> and the phage cocktail against <italic>P. mirabilis</italic> isolates</title>
<p>The antimicrobial activity of AME was previously assessed against strong biofilm-forming MDR <italic>P. mirabilis</italic> isolates. The results showed that the bulk plant extract had the best biofilm inhibition at a 125&#xa0;&#x3bc;g/mL concentration against all isolate (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>) (<xref ref-type="bibr" rid="B20">Mirzaei et al., 2022a</xref>). A MIC assay on 12 selected isolates treated with AME demonstrated no antibacterial activity in any extract concentration. The lytic phages Isf-Pm1 (<italic>Casjensviridae, Lavrentievavirus</italic>, accession number <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/OL741431.1/">OL741431</ext-link>) and Isf-Pm2 (<italic>Straboviridae, Tequatrovirus</italic>, accession number <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/OL741431.1/">OL741432</ext-link>) have been previously shown to be active against the biofilm of the isolates efficiently. The optimal efficacy of phage cocktail was determined at MOI1 (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>) (<xref ref-type="bibr" rid="B22">Mirzaei et al., 2022b</xref>).</p>
<p>When the AME was tested for antiphage activity, no significant reduction of the phage count was observed at bulk concentrations of 1,000&#xa0;mg/mL or lower (<italic>p</italic> &#x3e; 0.05; <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>).</p>
</sec>
<sec id="s4-2">
<title>The anti-QS, antibiofilm, and adhesion activity of a combination of AME and phage cocktail</title>
<p>Lower concentrations of the plant extract (125&#x2013;1,000&#xa0;&#x3bc;g/mL) clearly caused an increase in the anti-QS activity of MDR isolates. Overall, the combination of AME and phage cocktails exhibited no significant difference in anti-QS activity when compared to AME individual control (<italic>p</italic> &#x3e; 0.05, <xref ref-type="fig" rid="F1">Figure 1</xref>). However, AME alone and in combination with the phage cocktail significantly reduced QS activity in all cases.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Effects of combined AME and Phage cocktail on QS activity using <italic>J. lividum</italic> ATCC 12472. Heatmap represents OD<sub>620</sub>&#xa0;nm measurements of the violacein. Synogram represents the mean reduction (% of the control) of the treatment from the three replicates (P &#x3e; 0.05). Eugenol was used as a positive anti-QS control, and DMSO was used as a negative control.</p>
</caption>
<graphic xlink:href="fphar-15-1483055-g001.tif"/>
</fig>
<p>The biomass of MDR <italic>P. mirabilis</italic> biofilm was significantly reduced by 73% after treatment with the combination of phage cocktail (MOI 1) and AME at 125&#xa0;&#x3bc;g/mL compared to the control (<italic>p</italic> &#x3c; 0.0001), and remained at a similar level for the extract-only therapy (<xref ref-type="fig" rid="F2">Figure 2</xref>). Compared to combination therapy and control, the phage cocktail did not significantly alter bacterial multiplication at a high concentration (MOI 10). The combined treatment at higher concentrations did not show a significant effect on decreasing the bacterial biomass.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> Heat-map of combined phage cocktail-extract in biofilm of host bacteria. <bold>(B)</bold> Comparison of biofilm reduction percentage at different treatment with AME, Phage and combination. AME and Phage cocktail at different concentrations and MOIs. The statistical method used was the One-way ANOVA with Dunnett&#x2019;s test.</p>
</caption>
<graphic xlink:href="fphar-15-1483055-g002.tif"/>
</fig>
<p>The adhesion assay on Vero cells showed that the combined treatment of phage cocktail (MOI 1) and the extract (125&#xa0;&#x3bc;g/mL) decreased the adhesion of the bacteria to the Vero cells with 1.85 and 1.34 log as compared to the control and phage alone, respectively (P &#x3c; 0.0001, <italic>p</italic> &#x3d; 0.0002) (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effect of combined phage cocktail-extract on adhesion of <italic>P. mirabilis</italic> to a Vero cell line at optimum concentrations (MOI 1, and 125/mL, respectively). The statistical method used was the One-way ANOVA with post-hoc Tukey test. The stars represent as mentioned, &#x2a;&#x2a;&#x2a;&#x2a;: P&#x3c; 0.0001, &#x2a;&#x2a;&#x2a;: P &#x3d; 0.0002.</p>
</caption>
<graphic xlink:href="fphar-15-1483055-g003.tif"/>
</fig>
</sec>
<sec id="s4-3">
<title>Phantom bladder model</title>
<p>As demonstrated in <xref ref-type="fig" rid="F4">Figure 4</xref>, the phage cocktail alone, AME alone, and the combined therapy all significantly reduced levels of encrustation as compared to the control. There was no difference in urine pH after treatment with the extract alone, or in combination with phage cocktail when compared to the control.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Calcium deposition on the catheter (ppm per section of catheter). Phage cocktail, AME, and combined extract-phage significantly reduced levels of encrustation as compared to the control. The statistical method used was the One-way ANOVA with Dunnett&#x2019;s test and the P-value was calculated (P &#x3c; 0.0001).</p>
</caption>
<graphic xlink:href="fphar-15-1483055-g004.tif"/>
</fig>
</sec>
<sec id="s4-4">
<title>Scanning electron microscopy for biofilm analysis</title>
<p>SEM micrograph revealed that the treatment led to changes in disruption of the polysaccharide matrix of biofilm and bacterial morphology (<xref ref-type="fig" rid="F5">Figures 5 B, C</xref>) as compared to the untreated control (<xref ref-type="fig" rid="F5">Figures 5A</xref>). Combined phage cocktail-AME treated biofilm induced more cell lysis and biofilm destruction compared to phage or AME alone treatment (<xref ref-type="fig" rid="F5">Figures 5D</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>SEM micrographs of <italic>P. mirabilis</italic> biofilm. <bold>(A)</bold> biofilm of untreated <italic>P. mirabilis</italic> ATCC7002 control (without AME and Phage cocktail) showing bacterial cell condensation, and strong biofilm formation along with exopolysaccharide; <bold>(B)</bold> biofilm reduction using 125&#xa0;&#x3bc;g/mL AME alone, in which the biofilm architecture displays scratches-like structures; The arrow indicates the disruption of the polysaccharide matrix of the biofilm. <bold>(C)</bold> phage cocktail treatment at MOI 1, led to changes in both bacterial morphology and the matrix structure; <bold>(D)</bold> combined phage cocktail (MOI 1) and AME (125&#xa0;&#x3bc;g/mL) treatment showing efficient biofilm destruction and removal.</p>
</caption>
<graphic xlink:href="fphar-15-1483055-g005.tif"/>
</fig>
</sec>
<sec id="s4-5">
<title>Real-time PCR of QS- and adhesion-related genes of combined therapy</title>
<p>The effect of the combined phage cocktail - extract at optimum concentrations on the expression of QS- and adhesion-related genes, including <italic>mrp</italic>A, <italic>pmf</italic>A, <italic>lux</italic>S, <italic>rsm</italic>A, and <italic>rsb</italic>A, was evaluated for <italic>P. mirabilis</italic> ATCC after 4, 16, and 48&#xa0;h. Expression of all examined genes was significantly downregulated after 16&#xa0;h post-treatment with a combination of phage cocktail and AME ranging from 63% to 98% in comparison with the negative control (P&#x3c; 0.0001) (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>
<bold>(A)</bold> Downregulation of <italic>mrp</italic>A, <italic>pmf</italic>A, <italic>rsb</italic>A, <italic>rsm</italic>A and <italic>lux</italic>S genes in <italic>P. mirabilis</italic> ATCC7002 in combined AME and Phage cocktail at optimal concentration and MOI (125&#xa0;&#x3bc;g/mL, 1:1, respectively). The gene downregulation in combined treatment was more significant compared to individual treatment at 16-hour treatment (P &#x3c; 0.0001). <bold>(B)</bold> Relative expression levels of the <italic>mrp</italic>A, <italic>pmf</italic>A, <italic>rsb</italic>A, <italic>rsm</italic>A, and <italic>lux</italic>S genes in various treatments with AME (125&#xa0;&#x3bc;g/mL), phage cocktail (1:1,10<sup>8</sup>&#xa0;PFU/mL), and their combination at optimal concentration and exposure time (16&#xa0;h).</p>
</caption>
<graphic xlink:href="fphar-15-1483055-g006.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s5">
<title>Discussion</title>
<p>Bacteriophage therapy represents a promising novel alternative approach for the treatment of urinary tract infections (UTIs) (<xref ref-type="bibr" rid="B2">Breijyeh et al., 2020</xref>). However, one of the major concerns of phage therapy is the emergence of bacterial mutants that are resistant to phages (<xref ref-type="bibr" rid="B37">Torres-Barcel&#xf3; et al., 2022</xref>). This disadvantage has been compensated by different strategies, such as using phage cocktails (<xref ref-type="bibr" rid="B11">Haines et al., 2021</xref>; <xref ref-type="bibr" rid="B13">Kim et al., 2021</xref>; <xref ref-type="bibr" rid="B12">Hatfull et al., 2022</xref>) and combined treatment with phages and antibiotics (<xref ref-type="bibr" rid="B18">Malik et al., 2021</xref>). Medicinal plants and their compounds are being interestingly investigated for antimicrobial effects (<xref ref-type="bibr" rid="B33">Sher, 2009</xref>). Previous studies have shown the increased antibacterial activity of combined plant extracts with various bacterial pathogens such as <italic>Streptococcus pyogenes</italic>, <italic>Staphylococcus aureus</italic>, <italic>Escherichia coli</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Acinetobacter baumannii, Salmonella typhi</italic> and <italic>Klebsiella pneumoniae</italic> (<xref ref-type="bibr" rid="B19">Manandhar et al., 2019</xref>; <xref ref-type="bibr" rid="B8">Danish et al., 2020</xref>; <xref ref-type="bibr" rid="B23">Mohanta et al., 2020</xref>). However, to date, very few studies have evaluated the antimicrobial activity of combined plant extract and phage cocktail against MDR bacteria. In this study, we assessed a strategy using the phage cocktail along with <italic>A. maurorum</italic> extract to control MDR <italic>P. mirabilis</italic> biofilm. Initially, the potential antiviral effect of the extract on the phage cocktail as antibacterial agents in the bacterial host was tested. The findings revealed that even higher concentrations of the AME exhibited no discernible impact on the titration and plaque-forming ability of the bacteriophage in the co-incubation assay, which makes the combined use of the compounds possible. Goldstein <italic>et al.</italic> observed a significant suppression of T2 bacteriophage replication in <italic>E. coli</italic> after combining with the cinnamon extract and cinnamaldehyde in a time exposure manner (<xref ref-type="bibr" rid="B10">Goldstein and Shumaker, 2019</xref>). In another study, Stachurska <italic>et al.</italic> reported that <italic>Echinacea purpurea</italic> (EP) and <italic>Ruta graveolens</italic> (RG) extracts at low concentrations show antiphage and bacterial stimulating activity. They proposed that the antagonism depends on the species of the phage and bacterial host (<xref ref-type="bibr" rid="B34">Stachurska et al., 2023</xref>).</p>
<p>In this study, we showed that the combination of AME and phage cocktails at optimal concentrations did not significantly reduce bacterial concentration when compared to the untreated or AME-treated control. However, the phage cocktail alone or in combination with the extract exhibits significant lytic activity against <italic>P. mirabilis</italic> isolates, which proposes that the phage cocktail drives the bacteriolytic activity. Our results agree with Pimchan et al.&#x27;s work on the plant extracts derived from <italic>Stephania suberosa</italic> roots, <italic>Oroxylum indicum</italic> fruits, and <italic>Boesenbergia rotunda</italic> rhizomes in combination with lytic phages against <italic>E. coli</italic>. They showed that the phages had no significant difference in antibacterial activity after 24&#xa0;h; however, phages with extract significantly reduced the bacterial content in all cases for up to 6&#xa0;h compared to the untreated and extract-only controls (<xref ref-type="bibr" rid="B27">Pimchan et al., 2018</xref>). Given the multifaceted nature of the interaction between the extract and phage on bacterial cells, several factors, such as the concentration and dosage of the extract or phage, as well as the duration of exposure, likely contribute to the observed variation in results. It is plausible that the interaction of the compounds within the extract and phage exerts influence over multiple aspects that merit consideration.</p>
<p>Moreover, the combined treatment&#x2019;s anti-QS activity showed no difference compared to phage individual treatments. These results suggest that the presence of the phage cocktail likely did not exert an influence on QS and that the extract component primarily drove the anti-QS. Leon Flix et al. showed that using <italic>P. aeruginosa</italic> supplemented with penicillic acid as a QS inhibitor caused increasing productive infections of stationary-phase cells by two lytic phages (<xref ref-type="bibr" rid="B14">Le&#xf3;n-F&#xe9;lix and Villica&#xf1;a, 2021</xref>). However, it is indisputable that QS exerts a significant influence on phage dynamics, impacting various aspects such as biofilm development, virulence, host colonization, and dispersal (<xref ref-type="bibr" rid="B29">Qin et al., 2017</xref>; <xref ref-type="bibr" rid="B36">Tan et al., 2020</xref>; <xref ref-type="bibr" rid="B31">Shah et al., 2021</xref>).</p>
<p>The effect of AME at a concentration of 125&#xa0;&#x3bc;g/mL, when compared to a combination of phage and AME, did not exhibit a statistically significant impact on the biofilm inhibition assay conducted <italic>in vitro</italic> using microtiter plates with crystal violet staining. However, contrasting findings were observed in the phantom bladder model and scanning electron microscopy (SEM) analysis, where the combination treatment demonstrated a noteworthy decrease, highlighting the condition-dependent outcomes obtained from combination therapy in an <italic>in vitro</italic> and stimulating <italic>in vivo</italic> model. Our results showed that the interaction of bacteria, phage, and extract is more complex and multifaceted than what can be observed under controlled laboratory conditions. Several possible reasons include biological complexity, microenvironmental factors, pharmacokinetics and metabolism, immune system interactions, tissue complexity and interactions, and systemic effects (<xref ref-type="bibr" rid="B24">Niu et al., 2019</xref>; <xref ref-type="bibr" rid="B28">Podlacha et al., 2021</xref>). The substantial reduction in calcium deposition on the urinary catheter and the decreased bacterial attachment to the cell, achieved by optimizing the titer of AME and phage, potentially result from a synergistic interplay involving phage receptors. In combination therapy, the effect and interaction of each compound used must be assessed. This suggests that there may be an interaction between the quorum quenching activity of the crude extract (inhibition of bacterial communication) and the phage cocktail, leading to enhanced biofilm disruption. The genes under investigation in this study demonstrated a clear linkage to both biofilm formation and the QS phenomenon. The observed downregulation of these genes aligns with the decrease in both biofilm formation and QS activity, providing evidence for the significance of gene expression in these processes.</p>
<p>Overall, our study provides insights into the diverse mechanisms through which the combination of phytochemicals and bacteriophages can exert their effects on bacterial behavior and biofilm formation. By understanding these mechanisms, we can potentially develop novel strategies for combating bacterial infections and addressing the challenges posed by biofilms.</p>
<p>The synergistic utilization of phage therapy in combination with AME holds promising potential in the context of reducing biofilm formation. This combination approach demonstrates a favorable outlook for mitigating biofilm-related challenges, particularly by diminishing bacterial attachment to receptor sites and significantly reducing encrustation levels. Consequently, the application of this synergistic combination, specifically in the context of coated catheters or other medical instruments, could prove to be highly effective in combating biofilm-associated complications.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>AM: Writing&#x2013;review and editing, Writing&#x2013;original draft, Visualization, Investigation, Formal Analysis, Data curation. BE: Writing&#x2013;review and editing. MG: Writing&#x2013;review and editing, Methodology. JW: Writing&#x2013;review and editing, Methodology. RL: Writing&#x2013;review and editing. SM: Writing&#x2013;review and editing, Supervision, Funding acquisition.</p>
</sec>
<sec sec-type="funding-information" id="s8">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was financially supported by Isfahan University of Medical Sciences, Isfahan, I.R. Iran through Grant No 398353.</p>
</sec>
<ack>
<p>This work was supported by Isfahan University of Medical Sciences, Isfahan, I.R. Iran, through Grant No. 398353.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2024.1483055/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2024.1483055/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image3.JPEG" id="SM1" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table1.DOCX" id="SM2" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.JPEG" id="SM3" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.JPEG" id="SM4" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<sec id="s12">
<title>Abbreviations</title>
<p>AMR: Antimicrobial resistance, AME: <italic>Alhagi maurorum</italic> extract, MDR: multi-drug resistant, SEM: Scanning electron microscopy, MOI: multiplicity of infection, MIC: minimum inhibitory concentration, ICU: intensive care units, PBS: phosphate-buffered saline, QS: quorum sensing, UTIs: urinary tract infections.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Jaber</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Awaad</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Moses</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Review on some antioxidant plants growing in Arab world</article-title>. <source>J. Saudi Chem. Soc.</source> <volume>15</volume>, <fpage>293</fpage>&#x2013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1016/j.jscs.2011.07.004</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breijyeh</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jubeh</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karaman</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Resistance of gram-positive bacteria to current antibacterial agents and overcoming approaches</article-title>. <source>Molecules</source> <volume>25</volume>, <fpage>2888</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25122888</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakkour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hammoud</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Farhat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>El Roz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ezzeddine</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ghssein</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Overview of <italic>Proteus mirabilis</italic> pathogenicity and virulence. Insights into the role of metals</article-title>. <source>Front. Microbiol.</source> <volume>15</volume>, <fpage>1383618</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2024.1383618</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheesman</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Ilanko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blonk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cock</surname>
<given-names>I. E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Developing new antimicrobial therapies: are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution?</article-title> <source>Pharmacogn. Rev.</source> <volume>11</volume>, <fpage>57</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.4103/phrev.phrev_21_17</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chenia</surname>
<given-names>H. Y.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Anti-<italic>quorum</italic> sensing potential of crude Kigelia africana fruit extracts</article-title>. <source>Sensors</source> <volume>13</volume>, <fpage>2802</fpage>&#x2013;<lpage>2817</lpage>. <pub-id pub-id-type="doi">10.3390/s130302802</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chokshi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sifri</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cennimo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Horng</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Global contributors to antibiotic resistance</article-title>. <source>J. Glob. Infect. Dis.</source> <volume>11</volume>, <fpage>36</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.4103/jgid.jgid_110_18</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Clokie</surname>
<given-names>M. R. J.</given-names>
</name>
<name>
<surname>Kropinski</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Lavigne</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2009</year>). <source>Bacteriophages</source>. <publisher-name>Springer</publisher-name>.</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danish</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hafeez</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antifungal and antibacterial activity of aloe vera plant extract</article-title>. <source>Biol. Clin. Sci. Res. J.</source> <volume>2020</volume>. <pub-id pub-id-type="doi">10.54112/bcsrj.v2020i1.4</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Fox-Moon</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Shirtliff</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2024</year>). &#x201c;<article-title>Urinary tract infections caused by <italic>Proteus mirabilis</italic>
</article-title>,&#x201d; in <source>Molecular medical microbiology</source> (<publisher-name>Elsevier</publisher-name>), <fpage>1299</fpage>&#x2013;<lpage>1312</lpage>.</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shumaker</surname>
<given-names>A. G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cinnamon extract and cinnamaldehyde inhibit the replication of t2 bacteriophage in <italic>E. coli</italic>: potential for use in antiviral and anticancer therapy</article-title>. <source>Res. and Rev. A J. Biotechnol.</source> <volume>9</volume>, <fpage>8</fpage>&#x2013;<lpage>17</lpage>.</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haines</surname>
<given-names>M. E. K.</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>F. E.</given-names>
</name>
<name>
<surname>Nale</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Mahony</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Van Sinderen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kaczorowska</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Analysis of selection methods to develop novel phage therapy cocktails against antimicrobial resistant clinical isolates of bacteria</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>, <fpage>613529</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2021.613529</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatfull</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Dedrick</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Schooley</surname>
<given-names>R. T.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Phage therapy for antibiotic-resistant bacterial infections</article-title>. <source>Annu. Rev. Med.</source> <volume>73</volume>, <fpage>197</fpage>&#x2013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-med-080219-122208</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Inhibition of antimicrobial-resistant <italic>Escherichia coli</italic> using a broad host range phage cocktail targeting various bacterial phylogenetic groups</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>, <fpage>699630</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2021.699630</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le&#xf3;n-F&#xe9;lix</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Villica&#xf1;a</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The impact of <italic>quorum</italic> sensing on the modulation of phage-host interactions</article-title>. <source>J. Bacteriol.</source> <volume>203</volume>, <fpage>e00687</fpage>. <pub-id pub-id-type="doi">10.1128/JB.00687-20</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leprince</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mahillon</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Phage adsorption to gram-positive bacteria</article-title>. <source>Viruses</source> <volume>15</volume>, <fpage>196</fpage>. <pub-id pub-id-type="doi">10.3390/v15010196</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Schmittgen</surname>
<given-names>T. D.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>. <source>methods</source> <volume>25</volume>, <fpage>402</fpage>&#x2013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magiorakos</surname>
<given-names>A.-P.</given-names>
</name>
<name>
<surname>Srinivasan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Carmeli</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Falagas</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Giske</surname>
<given-names>C. G.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>18</volume>, <fpage>268</fpage>&#x2013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malik</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nehra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Bacteriophage cocktail and phage antibiotic synergism as promising alternatives to conventional antibiotics for the control of multi-drug-resistant uropathogenic <italic>Escherichia coli</italic>
</article-title>. <source>Virus Res.</source> <volume>302</volume>, <fpage>198496</fpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2021.198496</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manandhar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Luitel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dahal</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>
<italic>In vitro</italic> antimicrobial activity of some medicinal plants against human pathogenic bacteria</article-title>. <source>J. Trop. Med.</source> <volume>2019</volume>, <fpage>1895340</fpage>. <pub-id pub-id-type="doi">10.1155/2019/1895340</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirzaei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nasr Esfahani</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ghanadian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moghim</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022a</year>). <article-title>Alhagi maurorum extract modulates <italic>quorum</italic> sensing genes and biofilm formation in <italic>Proteus mirabilis</italic>
</article-title>. <source>Sci. Rep.</source> <volume>12</volume>, <fpage>13992</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-18362-x</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirzaei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nasr Esfahani</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Raz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghanadian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moghim</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>From the urinary catheter to the prevalence of three classes of integrons, &#x3b2;-lactamase genes, and differences in antimicrobial susceptibility of <italic>Proteus mirabilis</italic> and clonal relatedness with rep-PCR</article-title>. <source>Biomed. Res. Int.</source> <volume>2021</volume>, <fpage>9952769</fpage>. <pub-id pub-id-type="doi">10.1155/2021/9952769</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirzaei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wagemans</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nasr Esfahani</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lavigne</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Moghim</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>A phage cocktail to control surface colonization by <italic>Proteus mirabilis</italic> in catheter-associated urinary tract infections</article-title>. <source>Microbiol. Spectr.</source> <volume>10</volume>, <fpage>e0209222</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1128/spectrum.02092-22</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohanta</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Biswas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jena</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Hashem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abd_Allah</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Mohanta</surname>
<given-names>T. K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Anti-biofilm and antibacterial activities of silver nanoparticles synthesized by the reducing activity of phytoconstituents present in the Indian medicinal plants</article-title>. <source>Front. Microbiol.</source> <volume>11</volume>, <fpage>1143</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2020.01143</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Straubinger</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Mager</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Pharmacodynamic drug&#x2013;drug interactions</article-title>. <source>Clin. Pharmacol. Ther.</source> <volume>105</volume>, <fpage>1395</fpage>&#x2013;<lpage>1406</lpage>. <pub-id pub-id-type="doi">10.1002/cpt.1434</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nzakizwanayo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hanin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>McCutcheon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dedi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Salvage</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Bacteriophage can prevent encrustation and blockage of urinary catheters by <italic>Proteus mirabilis</italic>
</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>60</volume>, <fpage>1530</fpage>&#x2013;<lpage>1536</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02685-15</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Toole</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Microtiter dish biofilm formation assay</article-title>. <source>JoVE J. Vis. Exp.</source> <volume>e2437</volume>, <fpage>2437</fpage>. <pub-id pub-id-type="doi">10.3791/2437</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pimchan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Eumkeb</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>A. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>
<italic>In vitro</italic> activity of a combination of bacteriophages and antimicrobial plant extracts</article-title>. <source>Lett. Appl. Microbiol.</source> <volume>66</volume>, <fpage>182</fpage>&#x2013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1111/lam.12838</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Podlacha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grabowski</surname>
<given-names>&#x141;.</given-names>
</name>
<name>
<surname>Kosznik-Kaw&#x15b;nicka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zdrojewska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Stasi&#x142;oj&#x107;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>W&#x119;grzyn</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Interactions of bacteriophages with animal and human organisms&#x2014;safety issues in the light of phage therapy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>, <fpage>8937</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22168937</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>
<italic>Quorum</italic> sensing influences phage infection efficiency via affecting cell population and physiological state</article-title>. <source>J. Basic Microbiol.</source> <volume>57</volume>, <fpage>162</fpage>&#x2013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1002/jobm.201600510</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocha</surname>
<given-names>S. P. D.</given-names>
</name>
<name>
<surname>Elias</surname>
<given-names>W. P.</given-names>
</name>
<name>
<surname>Cianciarullo</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Nara</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Piazza</surname>
<given-names>R. M. F.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Aggregative adherence of uropathogenic <italic>Proteus mirabilis</italic> to cultured epithelial cells</article-title>. <source>FEMS Immunol. Med. Microbiol.</source> <volume>51</volume>, <fpage>319</fpage>&#x2013;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-695X.2007.00308.x</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>V. L.</given-names>
</name>
<name>
<surname>Bona</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Pimentel-Elardo</surname>
<given-names>S. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A phage-encoded anti-activator inhibits <italic>quorum</italic> sensing in <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Mol. Cell</source> <volume>81</volume>, <fpage>571</fpage>&#x2013;<lpage>583.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2020.12.011</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chavan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bajpai</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Hanif</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Beyond antibiotics: phage-encoded lysins against Gram-negative pathogens</article-title>. <source>Front. Microbiol.</source> <volume>14</volume>, <fpage>1170418</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2023.1170418</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sher</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Antimicrobial activity of natural products from medicinal plants</article-title>. <source>Gomal J. Med. Sci.</source> <volume>7</volume>.</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stachurska</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mizieli&#x144;ska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ordon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nawrotek</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Combinations of Echinacea (Echinacea purpurea) and rue (Ruta gravolens) plant extracts with lytic phages: a study on interactions</article-title>. <source>Appl. Sci.</source> <volume>13</volume>, <fpage>4575</fpage>. <pub-id pub-id-type="doi">10.3390/app13074575</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stickler</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>S. D.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Modulation of crystalline <italic>Proteus mirabilis</italic> biofilm development on urinary catheters</article-title>. <source>J. Med. Microbiol.</source> <volume>55</volume>, <fpage>489</fpage>&#x2013;<lpage>494</lpage>. <pub-id pub-id-type="doi">10.1099/jmm.0.46404-0</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>de Carvalho</surname>
<given-names>L. N.</given-names>
</name>
<name>
<surname>R&#xf8;der</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Burm&#xf8;lle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Middelboe</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>High cell densities favor lysogeny: induction of an H20 prophage is repressed by <italic>quorum</italic> sensing and enhances biofilm formation in Vibrio anguillarum</article-title>. <source>ISME J.</source> <volume>14</volume>, <fpage>1731</fpage>&#x2013;<lpage>1742</lpage>. <pub-id pub-id-type="doi">10.1038/s41396-020-0641-3</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres-Barcel&#xf3;</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Buckling</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Mitigation of evolved bacterial resistance to phage therapy</article-title>. <source>Curr. Opin. Virol.</source> <volume>53</volume>, <fpage>101201</fpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2022.101201</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ullah</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Munir</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Badshah</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ghani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Poulson</surname>
<given-names>B. G.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Important flavonoids and their role as a therapeutic agent</article-title>. <source>Molecules</source> <volume>25</volume>, <fpage>5243</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25225243</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veiga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maria da Gra&#xe7;a</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Rossa</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Mengarda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stofella</surname>
<given-names>N. C. F.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>L. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Colorimetric microdilution assay: validation of a standard method for determination of MIC, IC50%, and IC90% of antimicrobial compounds</article-title>. <source>J. Microbiol. Methods</source> <volume>162</volume>, <fpage>50</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.mimet.2019.05.003</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zalewska-Pi&#x105;tek</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Phage therapy&#x2014;challenges, opportunities and future prospects</article-title>. <source>Pharmaceuticals</source> <volume>16</volume>, <fpage>1638</fpage>. <pub-id pub-id-type="doi">10.3390/ph16121638</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>